0000950170-24-011389.txt : 20240205 0000950170-24-011389.hdr.sgml : 20240205 20240205180220 ACCESSION NUMBER: 0000950170-24-011389 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240201 FILED AS OF DATE: 20240205 DATE AS OF CHANGE: 20240205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Durgam Suresh K. CENTRAL INDEX KEY: 0001829958 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 24597210 MAIL ADDRESS: STREET 1: C/O INTER-CELLULAR THERAPIES, INC. STREET 2: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 4 1 ownership.xml 4 X0508 4 2024-02-01 0001567514 Intra-Cellular Therapies, Inc. ITCI 0001829958 Durgam Suresh K. C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET NEW YORK NY 10016 false true false false EVP, Chief Medical Officer true Common Stock 2024-02-01 4 A false 11860 0 A 11860 D Common Stock 2024-02-02 4 S false 2320 66.69 D 9540 D Common Stock 2024-02-02 4 S false 3847 67.49 D 5693 D Represents shares issued upon the vesting of performance stock units. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of performance stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.1734 to $67.1, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.15 to $68.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. /s/ Lawrence J. Hineline, Attorney-in-fact 2024-02-05